Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough...
Hence then, the article about trevi therapeutics to host conference call and webcast on june 2nd to share topline results from the phase 2b coral trial of haduvio in patients with idiopathic pulmonary fibrosis chronic cough was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough )
Also on site :
- Russia exposed plot to blow up Black Sea gas pipelines – Putin
- NATO nations could transfer nuclear bomb to Ukraine – Russian intelligence
- Discord cuts ties with Peter Thiel-backed verification software after its code was found tied to U.S. surveillance efforts